This article is more than 5 years old. Information may no longer be current.

FDA approves Eylea 12-week dosing for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a supplemental biologics license application for a 12-week dosing schedule of Eylea injection in wet age-related macular degeneration patients, Regeneron announced in a press release.

The FDA previously issued a complete response letter to Regeneron regarding the sBLA, which is based on data from the phase 3 VIEW 1 and 2 trials, in which wet AMD patients received Eylea (aflibercept) injections at least every 12 weeks, with additional doses as needed.

“We are pleased that the FDA has approved an updated label for Eylea,” George D. Yancopoulos, MD, PhD, president and chief scientific officer at Regeneron, said in the release. “Providing information to retinal physicians about the visual outcomes with a modified 12-week dosing schedule will help physicians make the most informed choices in treating patients suffering from wet age-related macular degeneration.”

Eylea was already approved for dosing intervals of every 4 weeks or every 8 weeks, after three initial monthly doses, for wet AMD.